Figure 2.
Overall survival. KIR3DL2+ (blue) vs KIR3DL2− (red) patients with all subtypes of ATL (A) and with aggressive ATL subtypes (acute and lymphoma types) (B).

Overall survival. KIR3DL2+ (blue) vs KIR3DL2− (red) patients with all subtypes of ATL (A) and with aggressive ATL subtypes (acute and lymphoma types) (B).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal